The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation.
Natural killer (NK) cells are lymphocyte effectors that are activated to control certain microbial infections and tumors. Many NK-activating and regulating receptors are involved in regulating NK cell function. In addition, activation of naïve NK cells is fundamentally triggered by cytokines or myeloid dendritic cells (mDC) in various modes. In this study, we synthesized 16 S-[2,3-bis(palmitoyl)propyl]cysteine (Pam2Cys) lipopeptides with sequences designed from lipoproteins of Staphylococcus aureus, and assessed their functional properties using mouse (C57BL/6) bone marrow-derived DC (BMDC) and NK cells. NK cell activation was evaluated by three criteria: IFN-gamma production, up-regulation of NK activation markers and cytokines, and NK target (B16D8 cell) cytotoxicity. The diacylated lipopeptides acted as TLR2 ligands, inducing up-regulation of CD25/CD69/CD86, IL-6, and IL-12p40, which represent maturation of BMDC. Strikingly, the Pam2Cys lipopeptides induced mouse NK cell activation based on these criteria. Cell-cell contact by Pam2Cys peptide-stimulated BMDC and NK cells rather than soluble mediators released by stimulated BMDC induced activation of NK cells. For most lipopeptides, the BMDC TLR2/MyD88 pathway was responsible for driving NK activation, while some slightly induced direct activation of NK cells via the TLR2/MyD88 pathway in NK cells. The potential for NK activation was critically regulated by the peptide primary sequence. Hydrophobic or proline-containing sequences proximal to the N-terminal lipid moiety interfered with the ability of lipopeptides to induce BMDC-mediated NK activation. This mode of NK activation is distinctly different from that induced by polyI:C, which is closely associated with type I IFN-inducing pathways of BMDC. These results imply that the MyD88 pathway of BMDC governs an alternative NK-activating pathway in which the peptide sequence of TLR2-agonistic lipopeptides critically affects the potential for NK activation.
Azuma
Masahiro
M
Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Sawahata
Ryoko
R
Akao
Yuusuke
Y
Ebihara
Takashi
T
Yamazaki
Sayuri
S
Matsumoto
Misako
M
Hashimoto
Masahito
M
Fukase
Koichi
K
Fujimoto
Yukari
Y
Seya
Tsukasa
T
D000818:Animals; D002460:Cell Line; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000166:cytology / Q000276:immunology*; D055666:Lipopeptides / Q000737:chemistry / Q000276:immunology*; D008074:Lipoproteins / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D053594:Myeloid Differentiation Factor 88 / Q000276:immunology; D013203:Staphylococcal Infections / Q000276:immunology*; D013211:Staphylococcus aureus / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000276:immunology*
D055666:Lipopeptides; D008074:Lipoproteins; C507780:Myd88 protein, mouse; D053594:Myeloid Differentiation Factor 88; C552442:S-(2,3-bis(palmitoyloxy)propyl)cysteine; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2
J Immunol. 2006 Sep 1;177(5):3162-9
16920954
J Exp Med. 2002 Feb 4;195(3):327-33
11828007
J Immunol. 2000 Nov 15;165(10):5392-6
11067888
J Biol Chem. 2009 Apr 3;284(14):9147-52
19218237
Nat Immunol. 2004 Oct;5(10):987-95
15454922
Immunity. 2009 Dec 18;31(6):873-84
19931471
Cell Mol Life Sci. 2008 Jun;65(11):1683-97
18327662
Int Immunol. 2006 Feb;18(2):355-62
16373361
J Immunol. 2004 Feb 15;172(4):2001-5
14764662
Cancer Res. 1988 Mar 15;48(6):1456-9
3345517
J Bacteriol. 2006 Apr;188(8):2761-73
16585737
J Exp Med. 2009 Dec 21;206(13):2967-76
19995959
Int Immunol. 2008 Sep;20(9):1155-67
18596023
Cell. 2007 Sep 21;130(6):1071-82
17889651
Infect Immun. 2000 Dec;68(12):6883-90
11083809
Cancer Sci. 2010 Feb;101(2):313-20
20059475
Cancer Sci. 2009 Aug;100(8):1494-501
19432881
J Biol Chem. 2006 Apr 7;281(14):9049-57
16455646
Trends Immunol. 2007 Sep;28(9):408-18
17681885
Int Immunol. 2001 Jul;13(7):933-40
11431423
Chembiochem. 2009 Sep 21;10(14):2311-5
19681087
Nat Immunol. 2001 Sep;2(9):835-41
11526399
Nat Rev Immunol. 2001 Oct;1(1):41-9
11905813
J Immunol. 2005 Feb 1;174(3):1566-73
15661917
Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12
18262679
J Immunol. 2001 Feb 15;166(4):2610-6
11160323
J Immunol. 2003 Oct 1;171(7):3675-83
14500665
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):252-7
17190817
J Immunol. 2009 Aug 15;183(4):2522-8
19635904
J Med Chem. 1991 Jul;34(7):1969-74
2066969
Nature. 2002 Nov 21;420(6913):324-9
12447441
Clin Diagn Lab Immunol. 2002 May;9(3):649-57
11986274
Nature. 2002 Nov 21;420(6913):329-33
12447442
J Immunol. 2002 Jul 1;169(1):10-4
12077222
Nat Immunol. 2003 Feb;4(2):161-7
12539043
Mol Ther. 2010 Jul;18(7):1379-88
20442710
Innate Immun. 2011 Apr;17(2):191-203
20130107
PLoS Pathog. 2010 Mar 12;6(3):e1000811
20300608
Cancer Immunol Immunother. 2009 Aug;58(8):1175-84
19184005